§ 01 Overview
Overview
C-terminal fragment of human growth hormone marketed for lipolytic effects without the IGF-1 or insulin resistance effects of full-length GH.
Phase IIb human trial (2007) showed no significant weight loss vs. placebo over 6 months. Popular in compounding despite negative outcome trial.
§ 02 Mechanism
Mechanism of action
AOD-9604 corresponds to the final 15 amino acids of hGH. It is proposed to stimulate lipolysis and inhibit lipogenesis without activating the GH receptor in a way that raises IGF-1 or disrupts glucose handling.
- 01Claimed lipolytic effects
- 02No measurable impact on IGF-1
- 03Generally well tolerated in trials
§ 03 Dosing
Dosing protocol
Standard Protocol
- Vial
- 5 mg
- BAC Water
- 2 ml BAC water
- Dose Range
- 200 – 500 mcg per dose
- Starting Dose
- 300 mcg
- Route
- SubQ
- Timing
- AM, empty stomach
- Frequency
- Daily
- Cycle
- 8–12 weeks
§ 04 Evidence
Evidence & research
Phase IIb human trial (2007) showed no significant weight loss vs. placebo over 6 months. Popular in compounding despite negative outcome trial.
FDA Status
Not FDA-approved as a drug; marketed as a cosmetic/research compound.
§ 06 News
In the news
2 articles from the last 12 months · updates hourly
AOD-9604 Peptide: Exploring Its Potential Influence in Scientific Research - Mid-Day
AOD-9604 Peptide: Exploring Its Potential Influence in Scientific Research Mid-Day
AOD 9604 Peptide: Expert Analysis Reviews Benefits and Side Effects for 2026 - Yahoo Finance
AOD 9604 Peptide: Expert Analysis Reviews Benefits and Side Effects for 2026 Yahoo Finance
§ 07 Sourcing
Sourcing & supply
Regulatory status
Restricted from compounding
Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales.
Research-use-only · 2
Limitless Life Nootropics
'Only BBB-accredited peptide company' (since 2020). Claims three-lab third-party testing. Broad catalog.
Core Peptides
Broad catalog, widest payment range. Mid-credibility: Knoji 2.5/5 and one scam-impersonation report.
Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →
§ 09 Safety
Safety & side effects
Side effects
- 01Minimal in trials
Contraindications
None specified.
§ 10 Questions
AOD-9604 FAQ
- What is AOD-9604?
- C-terminal fragment of human growth hormone marketed for lipolytic effects without the IGF-1 or insulin resistance effects of full-length GH. AOD-9604 corresponds to the final 15 amino acids of hGH. It is proposed to stimulate lipolysis and inhibit lipogenesis without activating the GH receptor in a way that raises IGF-1 or disrupts glucose handling.
- What is AOD-9604 used for?
- Reported uses include claimed lipolytic effects, no measurable impact on igf-1, and generally well tolerated in trials. Evidence strength is rated Experimental — see the evidence section for detail.
- How is AOD-9604 dosed?
- Commonly referenced dosing is 200 – 500 mcg per dose, typically daily, administered SubQ. This is educational reference only; consult a licensed clinician before use.
- How do you reconstitute AOD-9604?
- For AOD-9604, vials commonly come in 5 mg and a common reconstitution is 2 ml BAC water. Use the reconstitution calculator to convert any vial size and water volume into exact insulin-syringe units.
- What are the side effects of AOD-9604?
- Commonly reported side effects include minimal in trials. This list is not exhaustive.
- Is AOD-9604 legal?
- Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales. FDA status: Not FDA-approved as a drug; marketed as a cosmetic/research compound..